BRPI0518993A2 - composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto - Google Patents

composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto

Info

Publication number
BRPI0518993A2
BRPI0518993A2 BRPI0518993-4A BRPI0518993A BRPI0518993A2 BR PI0518993 A2 BRPI0518993 A2 BR PI0518993A2 BR PI0518993 A BRPI0518993 A BR PI0518993A BR PI0518993 A2 BRPI0518993 A2 BR PI0518993A2
Authority
BR
Brazil
Prior art keywords
compound
solvate
ester
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Application number
BRPI0518993-4A
Other languages
English (en)
Inventor
Erik Rytter Ottosen
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of BRPI0518993A2 publication Critical patent/BRPI0518993A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

COMPOSTO OU UM SAL, SOLVATO OU ÉSTER FARMACEUTICAMENTE ACEITÁVEL DO MESMO, COMPOSIÇçO FARMACÊUTICA, E, USO DE UM COMPOSTO. A invenção refere-se a novos compostos de fórmula (Ia) e (Ib), ditos compostos sendo úteis, p. ex., no tratamento de doenças inflamatórias oftálmicas, ou câncer.
BRPI0518993-4A 2004-12-13 2005-11-28 composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto BRPI0518993A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63500004P 2004-12-13 2004-12-13
DKPA200401942 2004-12-16
PCT/DK2005/000757 WO2006063585A1 (en) 2004-12-13 2005-11-28 Triazole substituted aminobenzophenone compounds

Publications (1)

Publication Number Publication Date
BRPI0518993A2 true BRPI0518993A2 (pt) 2008-12-23

Family

ID=37715934

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518993-4A BRPI0518993A2 (pt) 2004-12-13 2005-11-28 composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto

Country Status (23)

Country Link
US (1) US8293772B2 (pt)
EP (1) EP1828148B1 (pt)
JP (1) JP5015005B2 (pt)
KR (1) KR101260236B1 (pt)
CN (1) CN101115728B (pt)
AR (1) AR051792A1 (pt)
AT (1) ATE455768T1 (pt)
AU (1) AU2005316034B2 (pt)
BR (1) BRPI0518993A2 (pt)
CA (1) CA2590479A1 (pt)
DE (1) DE602005019093D1 (pt)
DK (1) DK1828148T3 (pt)
ES (1) ES2341473T3 (pt)
HR (1) HRP20100225T1 (pt)
IL (1) IL183513A0 (pt)
MX (1) MX2007006739A (pt)
NO (1) NO20073574L (pt)
PL (1) PL1828148T3 (pt)
PT (1) PT1828148E (pt)
RU (1) RU2394818C2 (pt)
UA (1) UA90698C2 (pt)
WO (1) WO2006063585A1 (pt)
ZA (1) ZA200704809B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003240482B2 (en) 2002-05-30 2009-03-12 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
US20100069609A1 (en) * 2006-06-21 2010-03-18 Erik Arstad Chemical methods and apparatus
US8080540B2 (en) 2006-09-19 2011-12-20 Abbott Products Gmbh Therapeutically active triazoles and their use
KR100932093B1 (ko) * 2006-09-27 2009-12-16 주식회사종근당 미세소관 형성 저해제로서 유용한 벤조페논 유도체
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
PL2225231T3 (pl) * 2007-12-18 2012-01-31 Actelion Pharmaceuticals Ltd Pochodne aminotriazolu jako agoniści ALX
CA2719243C (en) * 2008-03-26 2013-06-25 Chong Kun Dang Pharmaceutical Corp. Benzophenone thiazole derivatives useful for inhibiting formation of microtubule and method for producing the same
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
ES2927660T3 (es) 2008-06-16 2022-11-10 Univ Tennessee Res Found Compuestos para el tratamiento del cáncer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
RU2560677C2 (ru) 2009-12-22 2015-08-20 Лео Фарма А/С Кожная композиция, включающая аналог витамина d и смесь растворителя и поверхностно-активных веществ
MX2012007234A (es) 2009-12-22 2012-07-30 Leo Pharma As Nanocristales de monohidrato de calciprotiol.
ES2452872T3 (es) 2009-12-22 2014-04-03 Leo Pharma A/S Composición farmacéutica que comprende una mezcla solvente y un derivado o análogo de vitamina D
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
KR20120130777A (ko) 2010-03-01 2012-12-03 유니버시티 오브 테네시 리서치 파운데이션 암 치료용 화합물
KR101666759B1 (ko) * 2015-08-06 2016-10-18 경북대학교 산학협력단 1-벤조피란메틸-1h-1,2,3-트리아졸 유도체 및 이의 용도
CN106632285B (zh) * 2016-11-23 2019-11-01 河南师范大学 一种齐多夫定-1,2,3-三氮唑类化合物的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9701453D0 (en) 1997-01-24 1997-03-12 Leo Pharm Prod Ltd Aminobenzophenones
ATE251117T1 (de) 1999-07-16 2003-10-15 Leo Pharma As Neue aminobenzophenone
DK1202957T3 (da) 1999-07-16 2005-01-31 Leo Pharma As Aminobenzofenoner som inhibitorer for IL-1beta og TNF-alfa
ATE277891T1 (de) 1999-07-16 2004-10-15 Leo Pharma As Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
JP2003505362A (ja) 1999-07-16 2003-02-12 レオ・ファーマ・アクティーゼルスカブ ＩＬ−１βおよびＴＮＦ−αの抑制剤としてのアミノベンゾフェノン
JP2003505363A (ja) 1999-07-16 2003-02-12 レオ・ファーマ・アクティーゼルスカブ ＩＬ−１βおよびＴＮＦ−αの抑制剤としてのアミノベンゾフェノン
AU776395B2 (en) * 1999-12-06 2004-09-09 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Aminobenzophenones as inhibitors of IL-1beta and TNF-alpha
RU2270194C2 (ru) 2000-05-22 2006-02-20 Лео Фарма А/С Бензофеноны как ингибиторы il-1бета и tnf-альфа, фармацевтическая композиция и способ лечения
GB0107368D0 (en) * 2001-03-23 2001-05-16 Novartis Ag Organic compounds
WO2002083622A2 (en) 2001-04-10 2002-10-24 Leo Pharma A/S Novel aminophenyl ketone derivatives
KR100896667B1 (ko) 2001-08-28 2009-05-14 레오 파마 에이/에스 신규한 아미노벤조페논 및 이를 포함하는 약제학적 조성물
CA2510711A1 (en) 2002-12-20 2004-07-08 Leo Pharma A/S Novel aminobenzophenone compounds
CN1826310B (zh) * 2003-07-24 2010-07-21 利奥制药有限公司 新的氨基二苯酮化合物
US20090313239A1 (en) 2008-06-16 2009-12-17 Microsoft Corporation Adaptive Visual Similarity for Text-Based Image Search Results Re-ranking

Also Published As

Publication number Publication date
PT1828148E (pt) 2010-05-04
PL1828148T3 (pl) 2010-08-31
ATE455768T1 (de) 2010-02-15
DE602005019093D1 (de) 2010-03-11
DK1828148T3 (da) 2010-05-17
RU2394818C2 (ru) 2010-07-20
WO2006063585A1 (en) 2006-06-22
AR051792A1 (es) 2007-02-07
AU2005316034A1 (en) 2006-06-22
KR101260236B1 (ko) 2013-05-06
CN101115728B (zh) 2012-12-19
NO20073574L (no) 2007-07-10
UA90698C2 (en) 2010-05-25
EP1828148A1 (en) 2007-09-05
KR20070095945A (ko) 2007-10-01
US8293772B2 (en) 2012-10-23
US20060128766A1 (en) 2006-06-15
MX2007006739A (es) 2007-08-02
JP5015005B2 (ja) 2012-08-29
RU2007126648A (ru) 2009-01-20
ZA200704809B (en) 2008-08-27
EP1828148B1 (en) 2010-01-20
CA2590479A1 (en) 2006-06-22
JP2008523115A (ja) 2008-07-03
HRP20100225T1 (hr) 2010-07-31
ES2341473T3 (es) 2010-06-21
CN101115728A (zh) 2008-01-30
AU2005316034B2 (en) 2012-01-19
IL183513A0 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
BRPI0518993A2 (pt) composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
SV2002000245A (es) Oxazolidinonas substituidas y su uso ref. lea 34122-sv
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
BRPI0607545A2 (pt) composto, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
BRPI0915084B8 (pt) composto, e, composição farmacêutica
SE0402735D0 (sv) Novel compounds
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
DE602004024375D1 (de) Carboxamidderivate
TW200700392A (en) Novel compounds
EA200901155A1 (ru) Модуляторы фармакокинетических свойств терапевтических препаратов (варианты) и их использование в терапии
EA200802390A1 (ru) Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
UY30183A1 (es) Derivados de quinolina
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
UY29234A1 (es) Derivados de adamantano, composiciones farmacéuticas que los contienen, procedimientos de preparación de ambos y aplicaciones.
ECSP099177A (es) Derivados de quinazolinona e isoquinolinona
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
BRPI0517425A (pt) composto ou um sal, solvato, enanciÈmero, diastereÈmero ou mistura de diastereÈmeros do mesmo, composição farmacêutica, uso de composto
ATE529430T1 (de) Caspase-hemmer-propharmaka
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
UY29370A1 (es) Derivados de tiazol, composiciones que lo contienen, procedimientos de preparación y aplicaciones
TW200606164A (en) New compounds

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.